CAPTRUST Financial Advisors
ALLO icon

CAPTRUST Financial Advisors’s Allogene Therapeutics ALLO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Sell
79,197
-10,741
-12% -$23.6K ﹤0.01% 2940
2026
Q1 		$219K Buy
89,938
+36,837
+69% +$73.8K ﹤0.01% 2617
2025
Q4 		$72.7K Buy
53,101
+37,386
+238% +$49.3K ﹤0.01% 2644
2025
Q3 		$19.5K Buy
+15,715
New +$18.7K ﹤0.01% 2605
2022
Q3 		– Sell
-461
Closed -$5K – 2127
2022
Q2 		$5K Sell
461
-749
-62% -$6.65K ﹤0.01% 4055
2022
Q1 		$11K Buy
1,210
+1,192
+6,622% +$12.4K ﹤0.01% 3730
2021
Q4 		$0 Sell
18
-147
-89% -$2.59K ﹤0.01% 4755
2021
Q3 		$4K Hold
165
– – ﹤0.01% 4007
2021
Q2 		$4K Buy
+165
New +$4.71K ﹤0.01% 3927

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

CAPTRUST Financial Advisors's ALLO Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its Allogene Therapeutics (ALLO) stake by 12% in Q2 2026, selling an estimated $23.6K and leaving 79,197 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #2940.

CAPTRUST Financial Advisors first reported a position in ALLO in Q2 2021 and has held it in 9 quarters since. The position peaked at $219K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • CAPTRUST Financial Advisors held 79,197 shares of Allogene Therapeutics worth $165K as of Q2 2026.
  • CAPTRUST Financial Advisors sold 10,741 Allogene Therapeutics shares in Q2 2026, an estimated $23.6K.
  • Allogene Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2940 holding.
  • CAPTRUST Financial Advisors first reported a position in Allogene Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • CAPTRUST Financial Advisors's Allogene Therapeutics position peaked at $219K in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.